Follow LF0 researchXLinkedInSubstackFacebookTelegram
tput: No value for $TERM and no -T specified

Research

Schrödinger (SDGR) Stock Analysis & Research

Latest rating
Sell
Latest report
Aug 17, 2026
Reports
1
Sector
Healthcare

Schrodinger (SDGR) develops and licenses physics-based computational software for molecule discovery and optimization, and also runs collaborative and proprietary drug discovery programs on the same platform. In 2025, software revenue was $199.5M and drug discovery revenue was $56.4M.

Backtesting dashboard with equity curve and drawdown analysis
Quantitative market report dashboard with factor and risk analysis
SEC filing comparison with highlighted document changes